
Quarterly report 2024-Q1
added 05-17-2024
ThermoGenesis Holdings EBITDA 2011-2026 | THMO
Earnings before Interest, Taxes, Depreciation, and Amortization (EBITDA), is an often used measure of a company's profitability. Financial analysts use EBITDA for a number of purposes including calculating simple valuations of a firm, estimating cash flows, and assessing debt servicing capability. The uses for EBITDA in financial analysis are numerous, but in practice should be more restrained. While EBITDA has some useful applications, it should be used with caution, as the problems with EBITDA are abundant and can lead to a number of misguided conclusions.[1]
EBITDA is an important indicator for investors and analysts because it allows them to evaluate a company's operating profit without considering the impact of financial expenses, taxes, or non-cash depreciation and amortization. It provides better comparability between companies in different industries or with different tax conditions.
EBITDA is often used to assess a company's ability to generate cash flow and repay debts. It can also serve as a measure of a company's operational efficiency, as it shows how profitable the core business is, regardless of external factors such as interest or taxes.
However, it is important to note that EBITDA is not an official financial statement measure and can be defined and calculated differently by companies. Therefore, investors and analysts should exercise caution when using EBITDA as an evaluation tool and combine it with other financial metrics and information to get a more complete picture of a company's financial condition.
Annual EBITDA ThermoGenesis Holdings
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| -5.27 M | -6.6 M | -8.15 M | -3.93 M | -9.79 M | -8.41 M | -9.7 M | -13.5 M | -8.05 M | -4.69 M | -4.78 M | -2.37 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -2.37 M | -13.5 M | -7.1 M |
Quarterly EBITDA ThermoGenesis Holdings
| 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -223 K | - | - | - | -778 K | - | -1.35 M | -1.03 M | -1.06 M | - | -628 K | -2.82 M | -1.5 M | - | -514 K | -4.8 M | -1.01 M | - | -128 K | -72 K | -700 K | - | -1.76 M | -30.3 M | -3.1 M | - | -2.19 M | -1.56 M | -2.19 M | -3.57 M | -1.69 M | -5.05 M | -1.69 M | -1.97 M | -3.55 M | -1.31 M | -3.55 M | -4.24 M | -2.96 M | -3.69 M | -2.96 M | -1.6 M | -2.14 M | -1.28 M | -2.14 M | -558 K | 1.13 M | 266 K | 134 K | - | 99 K | 202 K | 99 K |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 1.13 M | -30.3 M | -2.32 M |
References
- Brockman, C. M., & Russell, J. W. (2012). EBITDA: use it... or lose it?. International Journal of Business, Accounting and Finance, 6(2), 84-93.
EBITDA of other stocks in the Medical devices industry
| Issuer | EBITDA | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Align Technology
ALGN
|
753 M | $ 174.53 | -1.3 % | $ 13.1 B | ||
|
Alphatec Holdings
ATEC
|
-4.64 M | $ 11.07 | -5.06 % | $ 1.66 B | ||
|
Bio-Rad Laboratories
BIO
|
421 M | $ 277.5 | -1.3 % | $ 7.83 B | ||
|
GenMark Diagnostics, Inc.
GNMK
|
-3.98 M | - | - | $ 1.77 B | ||
|
Acutus Medical
AFIB
|
-11.5 M | - | -26.83 % | $ 2.62 M | ||
|
AdaptHealth Corp.
AHCO
|
473 M | $ 12.22 | 0.33 % | $ 1.65 B | ||
|
Allied Healthcare Products
AHPI
|
-815 K | - | 3.58 % | $ 2.21 M | ||
|
Conformis
CFMS
|
-42.2 M | - | - | $ 16.4 M | ||
|
Obalon Therapeutics, Inc.
OBLN
|
-9.8 M | - | -5.86 % | $ 30.6 M | ||
|
EDAP TMS S.A.
EDAP
|
-17.9 M | $ 3.36 | -0.3 % | $ 126 M | ||
|
Cardiovascular Systems
CSII
|
-32.1 M | - | 0.15 % | $ 844 M | ||
|
Bruker Corporation
BRKR
|
437 M | $ 37.98 | -0.71 % | $ 5.66 K | ||
|
Cytosorbents Corporation
CTSO
|
-13.5 M | $ 0.6 | -2.45 % | $ 37.3 M | ||
|
Boston Scientific Corporation
BSX
|
4.98 B | $ 61.28 | -2.05 % | $ 90.7 B | ||
|
Apollo Endosurgery
APEN
|
-30.2 M | - | - | $ 475 M | ||
|
Dynatronics Corporation
DYNT
|
-1.97 M | - | 14.99 % | $ 929 K | ||
|
ClearPoint Neuro
CLPT
|
-23.4 M | $ 8.96 | -2.29 % | $ 254 M | ||
|
Electromed
ELMD
|
10.7 M | $ 24.41 | 0.04 % | $ 206 M | ||
|
CryoLife, Inc.
CRY
|
23.2 M | - | -4.14 % | $ 702 M | ||
|
Avinger
AVGR
|
-16.3 M | - | -20.74 % | $ 369 K | ||
|
Second Sight Medical Products
EYES
|
-27.1 M | - | -0.97 % | $ 54.4 M | ||
|
Axonics Modulation Technologies
AXNX
|
-53.2 M | - | - | $ 3.31 B | ||
|
Aziyo Biologics
AZYO
|
-24.1 M | - | 1.37 % | $ 20.5 M | ||
|
Soliton, Inc.
SOLY
|
-14.1 M | - | -1.42 % | $ 435 M | ||
|
Hancock Jaffe Laboratories, Inc.
HJLI
|
88.4 K | - | -1.98 % | $ 98.3 M | ||
|
GBS
GBS
|
-9.67 M | - | -0.57 % | $ 7.12 M | ||
|
Itamar Medical Ltd.
ITMR
|
-8.53 M | - | 0.03 % | $ 1.58 B | ||
|
Misonix, Inc.
MSON
|
-15.9 M | - | - | $ 462 M | ||
|
Neovasc
NVCN
|
-31.1 M | - | - | $ 111 M | ||
|
Globus Medical
GMED
|
757 M | $ 91.4 | -0.61 % | $ 12.4 B | ||
|
Butterfly Network
BFLY
|
-65.5 M | $ 4.15 | 0.24 % | $ 878 M | ||
|
Intersect ENT, Inc.
XENT
|
-64.8 M | - | - | $ 955 M | ||
|
BIOLASE
BIOL
|
-15.1 M | - | -13.19 % | $ 166 K | ||
|
Delcath Systems
DCTH
|
898 K | $ 9.88 | 0.3 % | $ 354 M | ||
|
BioSig Technologies
BSGM
|
-67.6 M | - | 37.08 % | $ 85.7 M | ||
|
Inogen
INGN
|
-9.55 M | $ 6.66 | -0.15 % | $ 177 M | ||
|
Inspire Medical Systems
INSP
|
64.9 M | $ 56.69 | 6.2 % | $ 1.66 B | ||
|
CONMED Corporation
CNMD
|
120 M | $ 36.93 | 0.93 % | $ 1.15 B | ||
|
IRIDEX Corporation
IRIX
|
-2.05 M | $ 1.04 | 0.97 % | $ 17.6 M | ||
|
Integer Holdings Corporation
ITGR
|
352 M | $ 86.67 | -0.93 % | $ 3.01 B | ||
|
FONAR Corporation
FONR
|
9.84 M | $ 18.61 | -0.05 % | $ 122 M | ||
|
Invacare Corporation
IVC
|
-65 M | - | - | $ 24.7 M | ||
|
Edwards Lifesciences Corporation
EW
|
1.42 B | $ 79.15 | -3.13 % | $ 46.3 B | ||
|
OrthoPediatrics Corp.
KIDS
|
-18.1 M | $ 15.94 | -0.44 % | $ 374 M | ||
|
Helius Medical Technologies
HSDT
|
-12.4 M | $ 1.89 | 0.53 % | $ 1.15 M | ||
|
LivaNova PLC
LIVN
|
228 M | $ 63.37 | -2.0 % | $ 3.46 B | ||
|
LENSAR
LNSR
|
-21 M | $ 5.46 | -1.27 % | $ 65.3 M | ||
|
Cutera
CUTR
|
-148 M | - | -10.19 % | $ 1.99 M |